Keytruda (Pembrolizumab)
Launch:
Keytruda was launched by Merck & Co. in 2014.
Manufacturer:
Merck & Co.
Global Sales in 2023:
In 2023, Keytruda achieved global sales of approximately $24 billion, making it one of the top-selling oncology drugs worldwide.
Why It’s the Best:
Keytruda is a groundbreaking immunotherapy drug that works by blocking the PD-1 pathway, allowing the immune system to target and destroy cancer cells more effectively. It is used to treat various cancers, including melanoma, non-small cell lung cancer, and head and neck cancer. Its success is due to its broad application across multiple cancer types and its role in significantly improving patient survival rates.